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Summary
The aim of this study was to investigate the pathogenesis of combination 
ipilimumab and nivolumab-associated colitis (IN-COL) by measuring gut-
derived and peripheral blood mononuclear cell (GMNC; PBMC) profiles. 
We studied GMNC and PBMC from patients with IN-COL, IN-treated 
with no adverse-events (IN-NAE), ulcerative colitis (UC) and healthy vol-
unteers using flow cytometry. In the gastrointestinal-derived cells we found 
high levels of activated CD8+ T cells and mucosal-associated invariant T 
(MAIT) cells in IN-COL, changes that were not evident in IN-NAE or 
UC. UC, but not IN-C, was associated with a high proportion of regula-
tory T cells (Treg). We sought to determine if local tissue responses could 
be measured in peripheral blood. Peripherally, checkpoint inhibition in-
stigated a rise in activated memory CD4+ and CD8+ T cells, regardless of 
colitis. Low circulating MAIT cells at baseline was associated with IN-COL 
patients compared with IN-NAE in one of two cohorts. UC, but not IN-
COL, was associated with high levels of circulating plasmablasts. In sum-
mary, the alterations in T cell subsets measured in IN-COL-affected tissue, 
characterized by high levels of activated CD8+ T cells and MAIT cells 
and a low proportion of Treg, reflected a pathology distinct from UC. These 
tissue changes differed from the periphery, where T cell activation was a 
widespread on-treatment effect, and circulating MAIT cell count was low 
but not reliably predictive of colitis.
Keywords: checkpoint inhibitor, colitis, ipilimumab, MAIT cells, nivolumab
Clinical and Experimental Immunology OrIgInal artIClE doi: 10.1111/cei.13502
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution 
and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
S. C. Sasson et al.
© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 202: 335–352
336
Introduction
Immune checkpoint inhibitors (ICI) target negative regula-
tors of cellular activation and include cytotoxic T lym-
phocyte antigen 4 (CTLA-4) (inhibited by ipilimumab) 
and programmed cell death 1 (PD-1; inhibited by pem-
brolizumab and nivolumab). The resulting dysregulated T 
cell activation enhances anti-tumour immunity, can lead 
to disease regression and increased survival in patients 
with metastatic melanoma and a variety of other malig-
nancies. While anti-CTLA-4 and anti-PD-1 therapies both 
independently improve survival in metastatic melanoma, 
the combination provides superior response rates and 
survival [1–3].
The augmented adaptive immunity induced by ICI comes 
at the cost of immune-related adverse events (irAE), most 
commonly affecting the skin, endocrine organs and gas-
trointestinal tract. Up to 44% of patients receiving com-
bination anti-CTLA-4 and PD-1 inhibition develop colitis, 
higher than is seen with anti-PD-1 monotherapy [1,4]. 
ICI-related colitis typically occurs within the first few 
treatment cycles (3–9  weeks) as a single-episode illness 
[5]. If not recognized and managed promptly ICI-related 
colitis can cause significant morbidity, and remains the 
most common drug-related cause of death from combina-
tion immune checkpoint inhibition [6].
Current guidelines advise corticosteroids as first-line 
treatment for ICI-related colitis, followed by intravenous 
steroids and anti-tumour necrosis factor (TNF)-α therapy 
(infliximab) for steroid-refractory disease. The management 
of ICI-related colitis has evolved from more classical forms 
of inflammatory bowel disease (IBD), but it is unclear 
how analogous the newer disease is. It is anticipated that 
a greater understanding of the underlying mechanisms of 
ICI-related colitis may lead to more effective 
treatments.
The intestinal environment poses distinct immunologi-
cal challenges, requiring tolerance to a diverse microbiome 
of commensals while mounting effective immunity to 
pathogens. While the pathogenesis of classical IBD is 
not fully elucidated, it is proposed that a breakdown 
of immune tolerance to bacterial species can contribute 
to disease development (reviewed in [7]). Propagation 
of intestinal inflammation is contributed to by multiple 
cell lineages, including epithelial cells, intestinal mac-
rophages, dendritic cells and innate lymphoid cells [7]. 
A dysregulated T cell response is thought to be a key 
driver of the chronic inflammation of IBD, as supported 
by the success of T cell-directed therapies including 
vedolizumab (targeting the α4β7 integrin) [8,9] and 
interleukin (IL)-12/23 p40 pathway inhibitors [10]. A 
recent study of gut-isolated mononuclear cells (GMNC) 
by flow cytometry demonstrated that both Crohn’s disease 
(CD) and ulcerative colitis (UC) were associated with 
a high proportion of CD4+ T cells and regulatory T 
cells (Treg) and lower proportions of CD8+ T cells com-
pared with tissue from healthy donors, changes that 
reversed during remission [11].
There are limited data on the pathogenesis of ICI-related 
colitis. Much of the literature relates to early use of ipili-
mumab monotherapy and histopathological evaluation of 
colon biopsies. Endoscopically, ICI-colitis is a heterogenous 
entity that shares features of both CD and UC [12], with 
the sigmoid colon and rectum usually involved. Initial reports 
found an increased number of CD8+ T cells in biopsies 
from ipilimumab-associated colitis that positively correlated 
with disease activity [13], while others found an increased 
proportion of infiltrating CD4+ T cells [14]. Up-regulation 
of T helper type 1 (Th1) [interferon (IFN)-γ] and Th17 
(IL-17) mRNA has been reported, as well as up-regulation 
of regulatory factors forkhead box protein 3 (FoxP3) and 
IL-10 [14]. While an inflammatory cell infiltrate and cryptitis 
can be evident on histopathology of ipilimumab-related 
colitis [14], detailed phenotyping of peripheral blood mono-
nuclear cells (PBMC) and GMNC in ICI-related colitis, 
including following a combination of ipilimumab and 
nivolumab, has not been studied to date.
Herein we characterized GMNC from patients treated 
with combination ipilimumab and nivolumab therapy who 
developed colitis (IN-COL), and compared these with those 
from patients who had no autoimmune adverse events 
(IN-NAE), patients during active UC flare and healthy 
volunteers. We additionally studied whether congruent 
change could be detected in the peripheral blood. We 
hypothesized that IN-COL is associated with an increased 
proportion of activated T cells [as defined by the well-
described co-expression of in-vivo activation markers 
human leucocyte antigen D-related (HLA-DR) and CD38 
[15–17] and a low proportion of Treg (CD4+CD25+CD127− 
[18] or CD4+25+FoxP3+ T cells), given the role of CTLA-4 
in their function [19–22].
Mucosal-associated invariant T (MAIT) cells, innate-
like T cells enriched in the mucosa [23], were also of 
interest. Human MAIT cells express high levels of CCR6 
and CD161 and a semi-invariant T cell receptor (TCR) 
α-chain (Vα7·2) [24]. MAIT cells are restricted by the 
major histocompatibility complex class I (MR1) molecule 
that recognizes vitamin B metabolites (e.g. riboflavin 
and folate) [25,26], but can also be activated by cytokines 
independently of their TCR [27]. The role of MAIT 
cells in health and disease is still being established [28]. 
They are predominantly effector cells that can produce 
high amounts of IFN-γ, cytotoxic granules including 
granzyme B, IL-17 and IL-22 with a mixed Th1/Th17 
phenotype [29]. There are data suggesting that MAIT 
cells play a regulatory role in some tissue but may be 
pathogenic in others (reviewed in [30]). Low circulating 
levels of MAIT cells have been reported in IBD [31–34], 
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where MAIT cell numbers accumulate in inflamed bowel 
and undergo activation-induced cell death [35]. MAIT 
cells are also depleted in the blood and gastrointestinal 
tissue of patients with coeliac disease [36]. MAIT cells 
[defined as chemokine receptor 6 (CCR6)+CD161+ or 
CD161+ TCR Vα7·2+] appear to play a protective role 
in graft-versus-host disease (GVHD; a condition that 
commonly affects the gastrointestinal tract), where the 
circulating CD8+CD161+ T cell count is lower in patients 
with acute GVHD and the circulating MAIT cell count 
inversely correlates to disease grade [37]. In mouse 
models, a higher proportion of MAIT cells protects 
against colonic GVHD [38].
We sought to measure what perturbations in these 
immune cell subtypes occurred in the gastrointestinal 
tissue and peripheral blood of patients with IN-COL and 
whether these changes were distinct from those seen in 
UC (Fig.1). We anticipate that a greater understanding 
of the cellular pathogenesis of ICI-associated colitis will 
eventually lead to improved and novel therapeutics.
Methods
Patients
Lymphocytes isolated from five pairs of endoscopically 
obtained ‘pinch’ colon biopsies were studied from 12 patients 
with melanoma treated with combination ipilimumab and 
nivolumab therapy in Oxford, UK (cohort 1). These included 
six patients with active IN-COL and six IN-NAE patients 
who were recruited as part of a larger longitudinal study 
collecting colonic biopsy from patients on ICIs at weeks 
7–10, regardless of colitis status [Predicting Immunotherapy 
Adverse Events (PRISE) Study]. Six patients with endo-
scopically and histologically confirmed active UC and six 
healthy volunteers undergoing benign polyp surveillance 
(with no pathology apparent on endoscopy) were studied 
as comparators. All patients provided written informed 
consent in line with local procedure (Oxford Centre for 
Histopathology Research 16/A019).
Viably cryopreserved PBMC from 20  treatment-naive 
patients with metastatic melanoma obtained from drug 
licencing trials were studied (cohort 2, from the Melanoma 
Institute, Australia). These included patients who received 
combination ipilimumab and nivolumab therapy and 
developed colitis (IN-COL; n = 9), and those who received 
combination ipilimumab and nivolumab who did not 
develop colitis nor (in order to prevent confounding) 
any autoimmune adverse events to date according to 
clinical record review (IN-NAE; n = 11). IN-COL PBMC 
were studied at baseline (i.e. prior to IN treatment) and 
at the time of colitis. We included blood samples taken 
up to 7  days preceding diagnostic endoscopy. IN-NAE 
were studied at baseline and weeks 7–10 of treatment 
(TX; a comparable time-point to time of colitis onset 
in the IN-COL group). These samples were compared 
with PBMC from patients with active UC (n  =  6) at a 
single time-point, where disease activity was determined 
by clinical assessment in those with an established diag-
nosis and by endoscopy and histopathological assessment 
for new cases. Healthy laboratory staff volunteers 
(n  =  17) were studied at a single time-point as controls. 
Written informed consent was obtained from each subject 
according to local institutional policy [Human Research 
Ethics Committee protocols from Royal Prince Alfred 
Hospital Protocol X15-0454 and HREC/11/RPAH/444, 
St Vincent’s Hospital, Sydney HREC/13/SVH/145, 
Westmead Hospital HREC/14/WMEAD/324(4081), 
Oxford Centre for Histopathology Research (16/A019 
and18/A064) and Oxford GI Biobank (REC16/YH/0247), 
Oxford, UK and Liverpool Hospital, Liverpool, UK (12/
NW/0525)].
PBMCs from 26 additional patients with melanoma 
receiving combination ipilimumab and nivolumab therapy 
were studied at therapeutic baseline in Oxford and 
Liverpool (cohort 3). These included 14  patients who 
went on to develop endoscopically confirmed IN-COL 
and 12  patients in whom nil adverse events were deter-
mined, i.e. any grade of irAE through clinical record 
review (IN-NAE). Patients who suffered a non-colitis 
irAE were excluded from the study from the outset due 
to concerns regarding potential confounding. These 
patients also provided written informed consent in line 
with local procedure (Oxford Centre for Histopathology 
Research 16/A019 and18/A064, Liverpool Hospital 12/
NW/0525). The baseline MAIT cell count was compared 
to that found in 35  community blood donors.
Isolation of mononuclear cells from gastrointestinal tissue
Endoscopically obtained pinch biopsies were collected 
from cohort 1 patients into Roswell Park Memorial Institute 
(RPMI) media containing penicillin and streptomycin and 
10% fetal calf serum. Biopsies underwent enzymatic and 
mechanical digestion by being transferred into 5  ml of 
warmed RPMI with penicillin and streptomycin/10% fetal 
calf serum with 1  mg/ml collagenase D (Sigma-Aldrich, 
St Louis, MO, USA) and 100 μg/ml DNAse I (ThermoFisher, 
Waltham, MA, USA) and shaken at 37°C for 1 h. Biopsies 
were then dissociated by vigorous agitation using a gentle 
MACS Dissociator (Miltenyi Biotech, Bergisch Gladbach, 
Germany) and strained through a 70 μm strainer. Freshly 
isolated GMNC were analysed.
Flow cytometry
For cohort 1 GMNC and cohort 3 thawed PBMC, the 
cellular subset analysis and MAIT cell count was per-
formed using a near infra-red live/dead stain (Invitrogen, 
S. C. Sasson et al.
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Carlsbad, CA, USA) and the following monoclonal anti-
bodies (mAb): CD3 phycoerythrin (PE)-CF594(UCHT1), 
CD4-BV650(SK3), CD8-AF700(SK1), CD38-fluorescein 
isothiocyanate (FITC)(HIT2), CD161-PE(HP-3G10), 
CCR6-BV421(G034E3), FoxP3(236A) (all BD Biosciences, 
San Jose, CA, USA), CD45RO-BV510(UCHL1), gran-
zyme-B-BV421(QA1828), HLA-DR-BV711(L243) 
(Biolegend, San Diego, CA, USA) and TCR Vα7·2-PE-
VIO770(REA175) (Miltenyi Biotec). Granzyme B and 
FoxP3 staining was performed using an intracellular and 
intranuclear permeabilization kit (ThermoFisher). Isotype 
control stains were performed using mouse immuno-
globulin (Ig)G2aκ, IgG1λ (BD Biosciences), IgG2b 
(Biolegend), IgG2aκ and REA control S antibody (Miltenyi 
Biotec).
For cohort 2, leucocyte subsets were identified on thawed 
PBMC using multiparameter flow cytometry, a near infra-red 
live/dead stain (Invitrogen) and the following mAb: CD3-
peridinin chlorophyll cyanin 5.5 (PerCPCy5.5)(UCHT1), 
CD4-BUV496(SK3), CD8-BUV-395(G42-8), CD19-BV785 
(SJ25C1), CD25-PE-Cy5(M-A251), CD27-allophycocyanin 
(APC)-R700(M-T271), CD27-PE-CF594(M-T271), CD38- 
PECy7(HIT2), CD45RA-BUV-737(HI100), CD56-APC 
(VNK75), CD127-BV785(HIL-7R-M21), CD161-APC(DX12), 
HLA-DR-BV711(G46-6), HLA-DR-FITC(G46-6), IgD-
BV421(IA6-2), IgM-PE(G20-127) (BD Biosciences), IgA-
APC(IS11-8E10), CD161-APC(191B8) (both Miltenyi Biotec), 
CD45-AF700(HI30) and CCR6-BV421(29-2L17) (Biolegend).
Flow cytometry was performed on a three-laser LSR Fortessa 
X-20 in the United Kingdom and a five-laser LSR Fortessa 
X-20 in Sydney (BD Biosciences) using FACSDIVA version 
8.0.1 software (BD Biosciences). Compensation was calculated 
before each experiment. Approximately 150  000 lymphocytes 
(50  000 live T cells) were analysed per colon biopsies and 
30  000 lymphocytes (10  000–15  000 live T cells) were ana-
lysed per PBMC sample. Gating strategies for both peripheral 
blood and gut-derived mononuclear cells are shown in 
Supporting information, Fig. S1. Lymphocyte populations are 
reported as a proportion of parent populations. Specifically, 
live CD3+ T cells are reported as a percentage of total live 
lymphocytes (as defined by side-scatter versus forward-scatter, 
CD45+ and exclusion of viability dye). MAIT cells are reported 
as a percentage of live T cells. Plasmablasts are reported as 
a percentage of live CD19+ lymphocytes. CD4+ and CD8+ 
T cells are reported as a percentage of live T cells. Activated 
(HLA-DR+CD38+) cells are reported as percentage of memory 
CD45RO+CD4+ or CD45RO+CD8+ T cells. Treg are reported 
as a percentage of CD4+ T cells.
MAIT cell gating strategy validation, risk factor study 
and MR1 tetramer staining
We validated the gating strategy of 
CD3+CD8+CD161+CCR6+ live lymphocytes used in cohort 
2 as a comparable measurement of MAIT cells to the 
‘gold-standard’ measurement of CD3+CD8+CD161+TCR 
Vα7·2+ live lymphocytes in cohort 3 patients with mela-
noma at baseline and 35  healthy blood donor controls.
Activation of gut-isolated MAIT cells was confirmed 
using human MR1/5-OP-RU tetramer provided by the US 
National Institute of Health Tetramer Facility (Emory 
University, Atlanta, GA, USA). Tetramers were generated 
using BV421-streptavidin (Biolegend), according to the NIH 
Tetramer Facility instructions. Tetramer staining was per-
formed using a 1/200 dilution in cellular suspension at 
room temperature for 40  min prior to washing with phos-
phate-buffered saline (PBS) + 0·05% bovine serum albumin 
(BSA)  +  1% ethylenediamine tetraacetic acid (EDTA) and 
proceeding with extracellular antibody staining.
Statistics
Differences between groups were determined using the 
unpaired non-parametric Mann–Whitney test. IN-COL 
samples at the point of colitis were compared with IN-COL 
at baseline, IN-NAE on 7–10 weeks treatment were com-
pared with IN-NAE at baseline and UC flare was compared 
with healthy volunteers and IN-COL patients at the point 
of colitis. Categorical data were compared by the non-
parametric χ2 test. Correlation analysis was performed 
using the non-parametric Spearman’s test. All were per-
formed using spss software (IBM, Armonk, NY, USA). 
Medians and interquartile ranges are reported throughout. 
A P-value  <  0·05 was considered statistically significant; 
where multiple comparisons were performed, a Bonferroni 
correction was made as detailed in individual figure 
legends.
The data sets used and/or analysed during the current 




The clinical characteristic of cohort 1, from which gut-
derived mononuclear cells were studied, are shown in 
Table 1). There were no significant differences between 
IN-COL and IN-NAE groups in regard to age, sex, mela-
noma stage, presence of visceral metastasis or serum 
LDH. Cohort 1 IN-C patients were managed with intra-
venous methylprednisone (IVMP; 33%), mycophenolate 
mofetil 500–1000 mg twice daily (17%), infliximab 5 mg/
kg (33%) or vedolizumab 300  mg at weeks 0, 2 and 6 
(17%). The clinical characteristics of patients with UC 
in cohort 1 are shown in Table 2). These patients had 
a median disease duration of 4  years and had been 
treated with mesalazine (three of six), azathioprine (one 
of six), infliximab (one of six) and adalimumab (one of 
six). The clinical, endoscopic and histopathological features 
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of cohort 1 IN-NAE, IN-COL and UC are shown in 
Table 3). Compared with the IN-COL group, UC patients 
were significantly younger (36 versus 66  years) and had 
a longer duration since the initial colitis diagnosis (48 
versus 1  month). There were no significant differences 
between IN-COL and UC groups in disease severity score 
using the Ulcerative Colitis Endoscopic Index of Severity 
(UCEIS) on the Nancy histological score (Table 3).
Clinical characteristics of patients in cohort 2, from 
which PBMC were studied, are shown in Table 4). All 
cohort 2 patients with colitis had high-grade disease con-
firmed by flexible sigmoidoscopy or colonoscopy and 
histopathology. The range of histopathological findings are 
given in Table 4). There was no significant difference 
between melanoma patient groups in terms of age, sex, 
melanoma stage or serum lactate dehydrogenase (LDH) 
level. The IN-COL colitis sample time-point did not differ 
significantly in terms of time (days) from the IN-NAE 
weeks 7–10 TX sample time-point. IVMP 1  mg/kg for 
1–3 days was used to manage IN-COL in 78% of patients 
and infliximab (IFX) 5  mg/kg given once was used in 
78% of IN-COL patients. The tumour response to ICIs 
was comparable between groups (IN-COL: progressive 
disease  =  4, stable disease  =  0; partial response  =  1; com-
plete response  =  4 and IN-NAE: progressive disease  =  3; 
stable disease  =  0; partial response  =  3; complete 
response  =  5). The clinical characteristics of patients with 
UC in cohort 2 are shown in Table 5). These patients 
had a disease duration of 5  years and had been treated 
with mesalazine (five of six), azathioprine (five of six), 
prednisone (four of six) and/or infliximab (three of six). 
All patients with UC were in a state of disease flare at 
the time of blood sampling as determined by clinical 
features and/or endoscopy and histopathology.
The clinical characteristics of patients in cohort 3 are 
shown in Table 6. Patients in the IN-COL and IN-NAE 
groups had no significant differences in age, sex, melanoma 
stage, proportion with visceral metastasis or serum LDH. 
There were no differences in IN-COL group patient fac-
tors between cohorts 2 and 3. With regard to the IN-NAE 
patients, cohort 3 had earlier stage disease compared with 
cohort 2 (P  <  0·05).
Fig. 1. Visual abstract. Peripheral blood and gut-infiltrating lymphocyte profiles are distinct between patients with anti-cytotoxic T lymphocyte 
antigen 4/programmed cell death 1 (CTLA-4/PD-1)-associated colitis [ipilimumab and nivolumab associated colitis (IN-COL)] and ulcerative colitis 
(UC). In gut-isolated lymphocytes, IN-COL is characterized by high proportions of T cells that are predominantly CD8+ and high levels of activated 
granzyme B+ mucosal-associated invariant T (MAIT) cells and a low proportion of regulatory T cells (Treg). This is distinct from UC, where there is a 
lower level of CD8+ T cell activation, no activation of MAIT cells and a high proportion of Treg. In the peripheral blood IN-COL is associated with 
widespread activation of CD4+ and CD8+ T cells in an ‘on-treatment’ effect not seen in UC. Both UC and IN-COL are associated with low proportions 
of MAIT cells; however, this was not a reliable predictor of IN-COL in a second cohort. UC, but not IN-COL, is associated with high levels of 
circulating plasmablasts.
S. C. Sasson et al.
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A high proportion of activated memory CD8+ T cells 
and paucity of Treg characterize the gastrointestinal 
tissue of patients with IN-COL
We first sought to understand the pathogenesis of IN-COL 
by direct study of the affected tissue. Patients with IN-COL 
had a T cell lymphocytosis (94% of lymphocytes) com-
pared with those in the IN-NAE group [63%; P  <  0·01; 
Fig. 2a(i)]. This could not be explained simply by a rise 
in total CD4+ or CD8+ T cells [Fig. 2a(iii) and (v)]. 
IN-treated patients had an inverted CD4  :  CD8 ratio in 
the gut tissue (i.e. a predominance of CD8+ T cells), 
which was distinct from both healthy volunteer gut and 
tissue from patients with UC [Fig. 2a(iii) and (v)]. However, 
perturbations in the CD4 : CD8 ratio did not differentiate 
between the IN-COL and IN-NAE groups. The proportion 
of activated memory CD4+ T cells was significantly elevated 
in GMNC of patients with IN-COL (22% of CD4+ T 
cells) compared with the IN-NAE group [1%; P  <  0·01; 
Fig. 2a(iv)]. The proportion of activated memory CD8+ 
T cells was significantly elevated in GMNC of patients 
with IN-COL (52% of CD8+ T cells) compared with the 
IN-NAE group [3%; P  <  0·01; Fig. 2a(vi)] and also with 
the UC group [10%; P  <  0·01; Fig. 2a(vii)]. The propor-
tion of activated memory CD8+ T cells was numerically 
greater than the proportion of activated memory CD4+ 
T cells. The proportion of activated memory CD8+ T 
cells was elevated in the GMNC of patients with UC 
(10% of CD8+ T cells) compared with healthy volunteers 
[1%; P  <  0·01; Fig. 2a(vi)]. Patients with UC had an 
elevated proportion of Treg (CD4+25+FoxP3+) compared 
with healthy volunteers [6% of CD4+ T cells compared 
with 1% P  <  0·01; Fig. 2a(ii) and b] and with IN-COL 
patients [3% P  <  0·01; Fig. 2a(ii) and 2b]. Patients with 
IN-COL did not have an elevated proportion of Treg 
compared with IN-NAE [3% compared to 1%; Fig. 2a(ii)].
High levels of MAIT cell activation are evident in the 
gastrointestinal tissue of patients with IN-COL
There was no significant difference between IN-COL and 
IN-NAE groups with regard to the MAIT cell count in 
Table 1. Clinical characteristics of cohort 1 IN-COL and IN-NAE groups
Cohort 1
Combination ipilimumab and 
nivolumab-related colitis (IN-COL)
Combination ipilimumab and nivolumab 
treated with nil adverse events (IN-NAE) P-value
Number (n) 6 6 n.a.
Age, median years (interquartile range) 66 (56–70) 56 (41–63) 0·22
Sex (n, % male) 4 (67) 2 (33) 0·25




Visceral metastases (n, %) 5 (83) 5 (83) > 0·99
Serum lactate dehydrogenase (LDH) 
median U/l (interquartile range)
284 (214–346) 235 (203–443) 0·70
Duration of IN-C (months) 1 (1-2) n.a. n.a.






Table 2. Clinical characteristics of cohort 1 healthy volunteers and UC groups
Cohort 1 Healthy volunteers Ulcerative colitis P-value
Number (n) 6 6 n.a.
Age, median years (interquartile range) 67 (50–78) 36 (25–46) 0·09
Sex (n, % male) 2 (33) 3 (50) 0.56
Duration of ulcerative colitis (median years and interquartile range) n.a. 4 (3–7) n.a.
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GMNC [Fig. 2c(i)]. IN-COL was associated with a signifi-
cantly higher proportion of HLA-DR+CD38+ activated MAIT 
cells (20% of MAIT cells) compared with the IN-NAE group 
[2%; P  >  0·01; Fig. 2c(ii)]. IN-COL was also associated with 
a greater proportion of granzyme B+ MAIT cells [19 versus 
0% of MAIT cells; P  <  0·05; Fig. 2c(iii)]. These changes did 
not occur in UC. We further confirmed activation of MAIT 
cells in the tissue using fluorescently conjugated tetramers 
to the MAIT TCR ligand (MR1-OP5) and confirmed that 
CD161+tetramer+ T cells were activated in IN-COL (19% 
HLA-DR+CD38+), but not IN-NAE (0·5%; Fig. 2d).
Finally, we confirmed that MAIT cell activation was 
greater in the gastrointestinal tract than in the peripheral 
blood by studying paired GMNC and PBMC in IN-COL 
(n = 3) and IN-NAE (n = 3). While patients with IN-COL 
had marginally higher MAIT cell activation measured in 
PBMCs compared with the IN-NAE group, this difference 
was more marked in the GMNC samples of two-thirds 
of patients (Fig. 2e).
Combination ipilimumab and nivolumab therapy 
induces a rise in circulating activated memory CD8+ 
and CD4+ T cells and activated memory gut-homing 
CD8+ T cells
We sought to determine if changes in the PBMC compart-
ment could be used as biomarkers for the changes seen in 
gastrointestinal tissue-derived lymphocytes in IN-COL. 
Treatment with combination ipilimumab and nivolumab 
therapy was associated with a rise in activated memory 
(CD45RA−HLA−DR+CD38+) CD8+T cells, regardless of the 
presence of colitis. In the IN-COL group the proportion of 
these cells were significantly elevated at the point of colitis 
(11% of memory CD8+ T cells) compared with baseline 
(0%; P  <  0·01; Fig. 3a,b). There was also a significant rise 
in the proportion of activated memory CD8+ T cells in the 
IN-NAE group following therapy (8% of memory CD8+  
T cells at weeks 7–10 compared with 1% at baseline; P < 0·01; 
Fig. 3a). The proportion of these cells did not differ between 
patients with active UC and healthy volunteers.
Table 3. Comparison of cohort 3 IN-NAE, IN-COL and UC clinical, endoscopic and histopathological findings
Cohort 1
Combination ipilimumab and 
nivolumab with nil adverse events 
(IN-NAE)





Number (n) 6 6 6
Age, median years (interquartile range) 55 (46–59) 66 (56–70) 36 (25–46)**
Sex (n, % male) 1 (17) 4 (67) 3 (50)
Duration of colitis (months) n.a. 1 (1–2) 48 (36–84)**
Endoscopic findings (UCEIS score)
0 6 0
1 0 2 0
2 0 0 1
3 0 1 0
4 0 1 1
5 0 2 1
6 0 0 3
7 0 0 0
8 0 0 0
Histological findings
Normal mucosa 6 0 0
Diffuse mild colitis 0 0 1
Lymphocytic colitis 0 1 0
Mild to moderate active UC with ulcers 0 0 1
Mild active chronic proctocolitis 0 0 2
Mild immunotherapy-related colitis 0 2 0
Moderate immunotherapy-related colitis 0 2 0
Moderate active chronic colitis 0 1 1
Severe active UC 0 0 1
Nancy score
0 6 0 0
1 0 2 0
2 0 1 2
3 0 3 2
4 0 0 2
**P < 0·01 compared with IN-COL. UCEIS = Ulcerative Colitis Endoscopic Index of Severity.
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Similarly, combination ipilimumab and nivolumab ther-
apy was also associated with a rise in activated memory 
(CD45RA−HLA-DR+CD38+) CD4+ T cells, regardless of 
the presence of colitis. The IN-COL group had 4% of 
activated memory CD4+ T cells compared with 0% at 
baseline (P  <  0·01; Fig. 3c,d). Patients in the IN-NAE 
group also displayed an increased proportion of activated 
memory CD4+ T cells following therapy (5% at weeks 
7–10 compared with 1% at baseline; P  <  0·01; Fig. 3c). 
The proportion of these cells did not differ between patients 
with active UC and healthy volunteers.
Absence of non-specific background staining for 
HLA-DR and CD38 was demonstrated using isotype control 
antibodies (Supporting information, Fig. S2a).





Combination ipilimumab and 
nivolumab treated with nil 
adverse events (IN-NAE) P-value
Number (n) 9 11 N.A.
Age, median years (interquartile range) 64 (53–67) 62 (55–70) 0·42
Sex (n, % male) 6(67) 6 (55) 0·69





Visceral metastases (%) 5(56) 10 (91) 0·07
Serum lactate dehydrogenase (LDH) median U/l (interquartile range) 227 (231–327) 251 (160–426) 1·00
IN-C ‘colitis’ time-point or IN-NAE TX time-point days, median 
(interquartile range)





4 1 n.a. n.a.
Colitis treatment (n, %) n.a. n.a.




Histopathological features n.a. n.a.
Diffuse active colitis 1
Granulomas present 2
Mild inflammation 1
Mild non-specific acute colitis 1
Mild to moderate acute colitis 1
Moderate to marked acute colitis 1
Severe acute proctocolitis 1
Mixed acute and chronic colitis 1
Chronic colitis 1
AJCC = American Joint Committee on Cancer; TX = treatment.
Table 5. Clinical characteristics of cohort 2 UC group
Cohort 2 Ulcerative colitis (UC)
Number (n) 6
Age, median years (interquartile range) 46 (25–53)
Sex (n, % male) 2 (33)
Duration of ulcerative colitis (years) 5 (2–8)






Active disease at time of blood sample (n, %)* 6 (100)
*According to clinical (six of six), endoscopic (three of six) and/or 
histopathological (three of six) criteria.
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Cohort 2 IN-COL patients had lower circulating MAIT 
cells at baseline compared with IN-NAE
Prior to therapy, cohort 2 patients who subsequently devel-
oped IN-COL had significantly lower circulating MAIT cells 
at baseline (0·0% of T cells) than those in the IN-NAE 
group (1·4%, P  <  0·02; Fig. 4a,b). This was also the case 
while on treatment, as IN-COL at the time of colitis (0·0%) 
had lower counts than those in the IN-NAE group at weeks 
7–10 of TX (0·7%; see Supporting information, Table S1). 
Patients with active UC had lower proportions of circulating 
MAIT cells (0·3%) compared with healthy volunteers (1·0%; 
P < 0·02; Fig. 4a). Absence of non-specific background stain-
ing for CD161 and CCR6 was demonstrated using isotype 
control antibodies (see Supporting information, Fig. S2bi).
There were no differences in the proportion of circulating 
CD25highCD127low Treg or CD45RA− memory Treg between 
those with IN-COL and IN-NAE, nor those with UC or 
healthy volunteers (see Supporting information, Table S1).
The PBMC compartment in patients with IN-COL is 
distinct from that of patients with active UC
We further explored if changes in the PBMC compart-
ment were similar between patients with IN-COL at the 
time of colitis and those with active UC. Compared with 
healthy volunteers, patients with active UC had a high 
proportion of CD19dimCD27+38high circulating plasmablasts 
(19% of B cells compared with 0%; P  <  0·01) that was 
not evident in patients with IN-COL (Fig. 5a,b); 55% of 
the circulating plasmablasts in patients with UC flare were 
IgA+ compared with 25% in healthy volunteers (P = 0·06). 
Additional differences in the PBMC compartment between 
patients with active UC and healthy volunteers are shown 
in Supporting information, Table S1.
Baseline circulating MAIT cell count and colitis in 
cohort 3
We sought to determine if baseline MAIT cell proportion 
could be used as a peripheral biomarker to predict IN-COL 
in a second distinct cohort in a blinded manner. Our 
validation of gating analysis using cohort 3 found a high 
correlation between the two results (R2  =  0·989; 
P  =  1·3  ×  10−72; Supporting information, Fig. S3a,b). 
Absence of non-specific background staining for CD161 
and TCR Vα7·2 was demonstrated in additional experi-
ments using isotype control antibodies (see Supporting 
information, Fig. S2bii). We confirmed in cohort 3 that 
melanoma patients who develop IN-COL (n  =  14) have 
a lower proportion of circulating MAIT cells compared 
with healthy volunteers (Fig. 4c). In contrast to cohort 2, 
where baseline MAIT cells was a useful discriminator 
Table 6. Clinical characteristics of cohort 3 IN-COL and IN-NAE groups
Cohort 3
Combination ipilimumab and 
nivolumab -related colitis (IN-COL)
Combination ipilimumab and nivolumab 
treated with nil adverse events (IN-NAE) P-value
Number (n) 14 12 n.a.
Age, median years (inter-quartile range) 62 (47–70) 59 (57–69) 0·59
Sex (n, % male) 11 (71) 4 (44) 0·38
Melanoma stage (AJCC version 8; n) * 0·11
M1a 4 5
M1b 2  3
M1c 8  1
M1d 0  0
 (Data not recorded) (0) (3)
Visceral metastases (%) 75 50 0·33
Serum lactate dehydrogenase (LDH) median U/l 
(interquartile range)
283 (209–618) 329 (272–351) 0·77
Colitis treatment (n, %) n.a. n.a.




Histopathological features n.a. n.a.
Mild inflammation 4
Focal acute cryptitis 2
Moderate colitis 1
Moderate to severe inflammation 1
Focal active proctitis 1
Chronic colitis 1
 (Data not available) (4)
AJCC = American Joint Committee on Cancer.
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between the IN-COL and IN-NAE groups, in cohort 3 
the IN-NAE patients also had a lower proportion of cir-
culating MAIT cells at baseline compared to healthy vol-
unteers, and there was no significant difference between 
IN-COL and IN-NAE MAIT cell proportions (Fig. 4c).
Discussion
The pathogeneses of ICI toxicities are poorly understood, 
with few known risk factors, biomarkers [4,39,40] or tailored 
therapies. As a result, clinicians cannot identify those at great-
est risk or intervene to alter therapy before morbidity occurs. 
Fig. 2. High levels of activated memory CD8+ T cells and mucosal-associated invariant (MAIT) T cells and low proportions of regulatory T cells (Treg) 
characterize the gastrointestinal tissue of cohort 1 patients with ipilimumab and nivolumab therapy-related colitis (IN-COL). Data from freshly 
isolated gut mononuclear cells from healthy volunteers (n = 6) and patients with active ulcerative colitis (UC; n = 6), those who received combination 
ipilimumab and nivolumab therapy with nil autoimmune adverse events (IN-NAE; n = 6) and those with combination ipilimumab and nivolumab 
therapy-associated colitis (IN-COL; n = 6), is shown. Median and interquartile range are displayed. TX = treatment: *P < 0·02 and **P < 0·01 by 
Mann–Whitney test. P-values < 0·02 were considered significant due to Bonferroni correction for multiple comparisons. (a) Compared with IN-NAE, 
patients in the IN-COL group had (i) a T cell lymphocytosis that was not explained by perturbations in the total (iii) CD4+ or (v) CD8+ subset. 
Patients with IN-COL had elevated (iv) activated memory CD4+ T cells and a greater proportion of (vi) activated memory CD8+ T cells compared 
with IN-NAE. The proportion of activated memory CD8+ T cells was greater than was seen in UC. (b) Compared with (i) healthy volunteers, patients 
with (iii) UC had a high proportion of forkhead box protein 3 (FoxP3)+CD25+ regulatory T cells (Treg) (gated) while a low proportion of Treg were seen 
in (ii) IN-COL. (c) Compared with the IN-NAE groups, patients with IN-COL had (i) no change in total MAIT cell proportion but (ii) a rise in 
activated and (iii) granzyme B+ MAIT cells. These changes were not seen in active UC. (d) Activation of MAIT cells in the gastrointestinal tissue was 
confirmed using a cell-specific MR1-OP5 tetramer that binds specifically to the MAIT T cell receptor (TCR). Data from thawed frozen gut-derived 
mononuclear cells are shown from a patient with IN-COL (i,ii) and IN-NAE (iii,iv) and gated on live CD3+ single cells. MR1-OP5 tetramer+CD161+ T 
cells in ii IN-COL displayed higher levels of activation compared with those in (iv) IN-NAE. (e) Paired data from thawed peripheral blood 
mononuclear cells (PBMC) and freshly isolated gut mononuclear cells from patients with combination ipilimumab and nivolumab therapy-associated 
colitis (IN-COL in red; n = 3) and those who received combination ipilimumab and nivolumab therapy with nil autoimmune adverse events (IN-NAE 
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For ICI-related colitis, diagnostic and treatment algorithms 
are being derived from classical forms of IBD and have not 
been completely validated in this new clinical setting.
Here we applied multiparameter flow cytometry to the 
study of gut-infiltrating and circulating lymphocytes from 
melanoma patients treated with combination ipilimumab 
and nivolumab therapy in the hope of finding novel insights 
into disease pathogenesis.
We began by directly investigating the profile of gut-
infiltrating lymphocytes in affected patients (cohort 1). Here, 
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we found that IN-COL was characterized by a predominantly 
CD8+ T cell lymphocytosis, with the proportion of activated 
memory CD8+ T cells greater than observed in active UC, 
and supports earlier reports suggesting T cell checkpoint 
inhibitor-related colitis is dominated by CD8+ T cells [13]. 
The high proportion of Treg evident in the gastrointestinal 
tissue of patients with UC was not evident in IN-COL, and 
we propose that this is due to Treg regulatory mechanisms 
involving a high expression of CTLA-4 [41–43]. IN-COL 
was associated with a higher proportion of activated and 
granzyme B+ MAIT cells compared with IN-NAE, changes 
that were not found in active UC, again highlighting the 
distinct pathology of IN-COL. We confirmed higher rates 
of MAIT cell activation in IN-COL using MAIT TCR-specific 
tetramer staining and paired peripheral blood and gut-isolated 
mononuclear cell samples from the same patients.
The comparison of IN-COL and UC patients in cohort 
1 (Table 3) is important. The IN-COL patients were older 
than UC patients and the time since first diagnosis of 
colitis was much shorter (1 versus 48  months). Despite 
this, the IN-C and UC cohorts scored comparably on 
both the UCEIS endoscopic and Nancy histopathological 
grading systems, two scales commonly used to score sever-
ity of UC. The higher levels of CD4+ and CD8+ T cell 
and MAIT cell activation measurable by flow cytometry 
in IN-COL did not correspond with higher UCEIS or 
Nancy scores. Therefore, the significant cellular changes 
found in IN-COL does not appear to be simply a func-
tion of colitis severity; however, this will require confir-
mation in larger studies.
We sought to understand if changes concordant with 
those seen in local tissue could be detected in the periph-
eral blood. We found therapy results in a widespread 
‘on-treatment’ activation of memory T cells; however, 
these were not predictive of colitis. We additionally deter-
mined that patients with IN-COL could also have pre-
existing lower circulating MAIT cells than those in the 
IN-NAE group, raising the possibility that a pre-existing 
reduction of peripheral MAIT cells might be a risk fac-
tor for IN-COL, as similarly described in other autoim-
mune diseases of the gastrointestinal tract [31–34,36,37]. 
However, this proved an unreliable predictor in cohort 
3, where the IN-NAE group also had low levels of cir-
culating MAIT cells. The differences between the IN-NAE 
groups in cohorts 2 and 3 could not be explained by 
significant differences in age, sex or serum LDH. 
Endoscopic evaluation was used in both cohorts to estab-
lish the diagnosis of colitis. There is a potential con-
founder, in that the IN-NAE patients in cohort 2 were 
at a higher melanoma stage compared with cohort 3.
IN-COL was not associated with high levels of circulat-
ing plasmablasts, a point of distinction from UC, possibly 
suggesting that there is less of a role of pathogenic B 
cells in IN-COL. Analysis of gut-derived mononuclear cells 
demonstrated that IN-COL was associated with high rates 
of predominantly activated memory CD8+ T cells and 
granzyme B+ MAIT cells, with a low proportion of Treg 
in a cellular pathology that was distinct from both IN-NAE 
and UC groups.
Our work provides further evidence that CD8+ T cells 
are the predominant cell type in IN-COL. Given that 
cytotoxic CD8+ T cells are thought to be the major 
target of ICI, it appears that their activation in IN-COL 
leads to off-target collateral damage. Important questions 
remain, including: why IN-COL occurs in some patients 
and not others; if there is any mechanism to predict 
this toxicity prior to treatment; and why steroid and 
infliximab-refractory cases occur. Our finding that both 
CD8+ T cells and MAIT cells are activated in IN-COL 
appears to provide important information regarding the 
initiating antigen, and suggests an interaction with the 
intestinal microbiome.
MAIT cells provide an important link between microbes 
and cellular immunity, being directly activated by vitamin 
B2 metabolites generated from bacteria or indirectly from 
cytokines (e.g. IFN-α and TNF-α). While we are unable 
Fig. 3. In cohort 2, treatment with combination ipilimumab and nivolumab therapy resulted in high levels of activated memory CD4+ and CD8+ T 
cells, independent of the presence of colitis. Data from thawed peripheral blood mononuclear cells (PBMC) from healthy volunteers (n = 17) and 
patients with combination ipilimumab and nivolumab therapy-associated colitis (IN-COL shaded red on graphs; n = 9), active ulcerative colitis, (UC 
n = 6) and those who received combination ipilimumab and nivolumab therapy with nil autoimmune adverse events (IN-NAE shaded blue on graphs; 
n = 11) is shown. Median and interquartile range are displayed. B/L = baseline, TX = on treatment for 7–10 weeks. **P < 0·01 by Mann–Whitney test. 
P-values < 0·02 were considered significant due to Bonferroni correction for multiple comparisons. (a) Patients in the IN-COL group had high levels 
of circulating activated memory CD45RA−human leucocyte antigen D-related (HLA-DR)+CD38+ CD8+ T cells at the point of active colitis compared 
with baseline. A significant rise in this subset was also seen in the IN-NAE groups following 7–10 weeks of therapy. (b) Gating strategy showing live, 
single lymphocytes that are CD3+8+CD45-RA−. (i) Healthy volunteers; (ii) patient with active UC; (iii) patient in the IN-COL group at baseline; (iv) 
results from the same IN-COL patient at the time of active colitis; (v) patient in the IN-NAE group at baseline; (vi) results from the same IN-NAE 
patient following treatment. (c) At the point of colitis IN-COL patients had high proportions of circulating activated memory CD45RA−HLA-
DR+CD38+CD4+ T cells. The percentage of these cells was elevated compared with baseline values. A rise in the percentage of these cells is also seen in 
the IN-NAE group following 7–10 weeks of treatment. (d) Gating strategy showing live, single lymphocytes that are CD45RA−CD3+4+. (i) Healthy 
volunteers; (ii) patient with active UC; (iii) patient in the IN-COL group at baseline; (iv) results from the same IN-COL patient at the time of active 
colitis; (v) patient in the IN-NAE group at baseline; (vi) results from the same IN-NAE patient following treatment.
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to confirm that low circulating MAIT cell counts defini-
tively correlate with subsequent risk of IN-COL, activated 
MAIT cells were only seen in the gut-isolated mononuclear 
cells of IN-COL and not IN-NAE patients. This raises 
important questions that centre around whether or not 
specific microbes are involved in MAIT cell activation 
in the setting of IN-COL and how MAIT cell trafficking 
is regulated, particularly between the blood and gut. There 
is literature suggesting a host’s microbiome can impact 
upon the efficacy of ICI therapy [44–46] and the devel-
opment of associated colitis [45] that is relevant to this 
field and that we are exploring in a prospective trial. 
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Additionally, there are data supporting the efficacy of 
faecal microbiota transplant for ICI-colitis [47], suggesting 
that replacement of microbiome species can ameliorate 
disease; one mechanism of this might be through reduc-
ing the provision of species-specific bacterial-derived 
MAIT cell ligands.
Fig. 5. Active ulcerative colitis (UC) but not combination ipilimumab and nivolumab therapy-related colitis (IN-COL) is associated with high 
circulating plasmablasts in cohort 2. Data from thawed peripheral blood mononuclear cells (PBMC) from healthy volunteers (n = 17) and patients 
with combination ipilimumab and nivolumab therapy-associated colitis (IN-COL shaded red; n = 9) active ulcerative colitis (UC, n = 6) and those 
who received combination ipilimumab and nivolumab with nil autoimmune adverse events (IN-NAE shaded blue; n = 11). Median and interquartile 
range shown. B/L = baseline, TX = on treatment for 7–10 weeks. **P < 0·01 by Mann–Whitney test. P-values < 0·02 were considered significant due to 
Bonferroni correction for multiple comparisons. (a) Patients with active UC had significantly elevated circulating CD19+27+38+ plasmablasts 
compared with healthy volunteers. This change was not seen in patients treated with combination ipilimumab and nivolumab therapy, including those 
with IN-COL. (b) Plasmablast gating strategy showing live, single CD19+ lymphocytes. (i) Healthy volunteers; (ii) active UC; (iii) IN-COL at time of 
colitis; (iv) IN-NAE at weeks 7–10.
Fig. 4. Low levels of circulating mucosal-associated invariant T (MAIT) cells at baseline in cohort 2 patients who developed combination ipilimumab 
and nivolumab therapy-related colitis. Data from thawed peripheral blood mononuclear cells (PBMC) from healthy volunteers (n = 17) and patients 
with combination ipilimumab and nivolumab therapy-associated colitis (IN-COL shaded red; n = 9), active ulcerative colitis (UC, n = 6) and those 
who received combination ipilimumab and nivolumab with nil autoimmune adverse events (IN-NAE shaded blue; n = 11). Medians and interquartile 
range are shown. B/L = baseline. **P < 0·02 by Mann–Whitney test. P-values < 0·02 were considered significant due to Bonferroni correction for 
multiple comparisons. (a) Cohort 2 patients in the IN-COL group at baseline had a paucity of MAIT cells compared with those in the IN-NAE group 
at baseline. Patients with active UC flare had lower circulating MAIT cell counts compared to healthy volunteers. (b) MAIT cell gating strategy 
showing live, single lymphocytes that are CD38+. (i) Patient in IN-COL group at baseline; (ii) patient in IN-NAE group at baseline; (c) low circulating 
MAIT cells at baseline was not predictive of IN-COL in cohort 3. In cohort 2 patients with melanoma who subsequently developed dual checkpoint 
colitis (IN-COL shaded red; n = 9) had significantly lower MAIT cell proportion at baseline compared to healthy volunteers (n = 17). Patients with 
melanoma treated with ipilimumab and nivolumab who did not develop any autoimmune side effects did not display reduction in MAIT cells 
(IN-NAE shaded blue; n = 11). In cohort 3 the median baseline MAIT cell count of both melanoma patient groups IN-COL (shaded red; n = 15) and 
IN-NAE (shaded blue; n = 9) was significantly lower than that of healthy volunteers (n = 35); however, there were no further differences between the 
patient groups. **P < 0·01 and ***P < 0·001 by Mann–Whitney test. P-values < 0·01 were considered significant due to Bonferroni correction for 
multiple comparisons.
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The presence of the riboflavin operon in bacteria identi-
fies species that can activate MAIT cells through their 
TCR. The activation of MAIT cells in this setting raises 
a compelling link between host microbiome, MAIT cells 
and IN-COL that warrants further investigation, especially 
in regard to whether these cells contribute to tissue dam-
age. A report investigating colitis in the setting of ipili-
mumab monotherapy found higher levels of riboflavin 
(vitamin B2) in the microbiome was associated with pro-
tection from colitis [44], providing a possible link to MAIT 
cells (that are activated by riboflavin metabolites) as pro-
tective in ICI-associated colitis.
MAIT cells can be activated by their TCR or cytokines 
(IL-12, IL-15, IL-18, IFN-α/β, TNF-α) or synergistically 
by both. We require further work to determine which 
pathways are leading to the activation of MAIT cells in 
IN-COL and whether this activity contributes to tissue 
damage [48–50].
This work provides an important first report on changes 
in gut-derived and peripheral-blood mononuclear cells that 
occur in ICI-associated colitis, but our approach has several 
limitations. This work constitutes retrospective and cross-
sectional analyses conducted in relatively small numbers 
of patients that requires confirmation in larger studies. We 
also cannot comment at this stage on whether these changes 
occur in anti-PD-1 monotherapy-associated colitis.
We are currently recruiting to a prospective single-centre 
study of oncology patients who have PBMC and GMNC 
collection, flexible sigmoidoscopy with gastrointestinal biopsy 
and microbiome analysis prior to commencement of ICI 
therapy, and at the time of subsequent development of related 
colitis. We aim to determine the mechanisms by which 
MAIT cells become activated in the gastrointestinal tract. 
Here we demonstrate that the levels of activated MAIT 
cells in the circulation are not a good indicator of the levels 
in the colon, and further investigation into how circulating 
MAIT cells relate to tissue-based populations would be of 
value. It is also unclear at this stage whether MAIT cell 
activation contributes to tissue damage or is part of a 
homeostatic repair mechanism. It is hoped that further 
understanding of the mechanisms that activate memory 
CD8+ T cells and MAIT cells in the gastrointestinal tract 
of patients with ICI-related colitis will lead to the develop-
ment of improved and novel targeted therapies.
Conclusions
The gastrointestinal tissue of patients with IN-COL is 
characterized by high levels of activated memory CD8+ 
T cells and MAIT cells. These changes were distinct from 
the peripheral blood compartment, where CD8+ T cell 
activation reflected an on-treatment effect and where the 
circulating MAIT cell count was significantly lower than 
in health, but neither could predict the onset of colitis 
(Fig. 1). Further work is required to determine the pathway 
by which CD8+ T cells and MAIT cells become activated 
in the gut of patients with ICI-associated colitis and 
whether MAIT cells contribute to tissue damage or repair. 
Advancements in this area have the potential to inform 
novel treatment strategies for this new and distinct inflam-
matory bowel disease.
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Fig S1. Peripheral blood and gut-derived mononuclear 
cell (PBMC; GMNC) flow cytometric gating strategies. 
Data from a) thawed PBMC from a healthy volunteer is 
shown. Gating strategy for i) lymphocytes ii) singlets iii) 
Live T cells iv) CD4+ and CD8+ T cells v) CD4+ naïve (Q2), 
effector memory (Q4), central memory (Q1) and T cells 
re-expressing CD45RA (Q4); Box includes all CD45RA− 
memory cells vi) Highly activated CD4+CD45RA− cells in 
Q2 vii) CD8+ naïve (Q2), effector memory (Q4), central 
memory (Q1) and T cells re-expressing CD45RA (Q4); 
Box includes all CD45RA− memory cells viii) Highly ac-
tivated CD8+CD45RA− cells in Q2. Data from b) Freshly 
isolated GMNC from a healthy volunteer is shown. The 
approach is different for GMNC given the very low pro-
portion of CD45RA+ and naïve T cells in the gut. Gating 
strategy for i) lymphocytes ii) singlets iii) Live T cells iv) 
CD4+ and CD8+ T cells v) CD4+CD45RO+vi) Highly acti-
vated CD4+CD45RO+ cells in Q2 vii) CD8+CD45RO+vi) 
Highly activated CD8+CD45RO+ cells in Q2.
Fig S2. Peripheral blood mononuclear cells (PBMC) stained 
with monoclonal isotype control antibodies. Data from 
thawed PBMC from a single healthy volunteer is shown 
gated on live, single T cells. (a) Isotype control histograms for 
HLA-DR versus CD38 in (i) CD8+ and (ii) CD4+ T cells. Cells 
are also stained for CD161, CCR6, CD45RO, CD25 as a com-
parator for Fig. 4b). (b) Isotype control histograms for CD161 
versus (i) CCR6 and (ii) TCRVα7.2. Cells are also stained for 
CD4, CD25, CD45RO to act as a comparator for Fig. 2d).
Fig S3. (a) Validation of CD161+CCR6+ CD8+ T cells as a 
corelate to CD161+Vα7.2+ CD8+ mucosal associated invari-
ant T (MAIT) cells in Cohort 2. Thawed peripheral blood 
mononuclear cells (PBMC) from healthy volunteers (N = 35; 
open circles) and patients with melanoma prior to treatment 
with ipilimumab and nivolumab (N = 24) were stained with 
markers for MAIT cells in a single flow-cytometric assay. Of 
the melanoma patients some subsequently developed T cell 
checkpoint-inhibitor-related colitis (N = 15; closed triangles) 
while others did not (N = 9; open triangles); p = 3.88x10-9 by 
Spearman’s correlation. (b) Alternative flow cytometric gat-
ing strategies for MAIT cells. Data from thawed PBMC from 
single healthy volunteer is shown. As depicted, lymphocytes 
were gated on, live T cells, single cells, CD8+ and then, gated 
on (i) CCR6 versus CD161 or (ii) T cell receptor chain 
Vα7.2. SSC = side scatter, FSC = forward scatter, NIR = near 
infra-red viability stain, H = height, A = area, TCR = T cell 
receptor.
Table S1. Characterisation of the peripheral blood mono-
nuclear cell (PBMC) compartment in patients with com-
bination ipilimumab and nivolumab-associated colitis. 
*P  <  0·05 **P  <  0·01 ***P  <  0·001 compared with healthy 
volunteers; †P < 0·05 ††P < 0·01 for combination ipilimumab 
and nivolumab-associated colitis (IN-COL) compared to 
baseline; ¶P < 0·05 ¶¶P < 0·01 for combination ipilimumab 
and nivolumab-treated patients with nil adverse events (IN-
NAE) compared to baseline. All refer to Mann-Whitney tests 
with no correction.
